Medicinal Products for Human Use - ICELAND

Competent authority

Contact Details	**Contact Name 1** Icelandic Medicines Agency (IMA) **Phone** 520 2100 **Fax** 561 2170 **Email Department** clinical.trials@ima.is **Address** Vínlandsleið 14 **ZIP/City** 113 Reykjavík **Country** Iceland (IS) **Web address** http://www.ima.is **Additional Information** No local CA.
Trial Authorisation / Registration / Notification	**Regulatory and ethics bodies involved in approval process** Competent Authority/-ies (CA) Ethics committee(s) Agency for data protection **CA - Submission for authorisation mandatory for** Clinical IMP trials Clinical ATMP trials **CA - Registration/ notification without approval required for** – **CA - Submission required to** National CA **Additional Information** Non-interventional trials do not need to be notified.
Submission of Application	**Responsible for study submission** Sponsor **Entitled to study submission** –

	Prerequisites for submission – **Guidance on submission of application** Related information on CT application procedure is available on the IMA website in section Home > Licences > Clinical Trials > Application. **Additional Information** Application to IMA and EC concerned can be done in parallel or in any order
Submission Format	**Format option(s)** Data carrier (USB key) Paper hardcopy Data carrier (CD-rom/DVD) **Preferred format** One paper hardcopy of the CTA and all data + CD ROM or USB flashdrive with all the documents **Standard application form available** Yes **Standard application form** European CT Application Form **Standard application form - Additional information** The relevant Checklist IMP (with or without marketing authorisation in the EEA) shall be completed and attached to the application (available on IMA website in section Clinical Trials > Application). **Guidance on submission format available** Yes **Guidance on submission format** Related information on CT application procedure is available on the IMA website in section Home > Licences > Clinical Trials > Application.
Language of Submission	**Language(s) of application** Icelandic English **Preferred language of application** – **English accepted** Yes **Documents mandatory to be in official national language** –
Submission Fees	**Fees for trial submission mandatory** Yes

Fees

Clinical Trial applications:
Clinical trials 212 000 ISK (approx. €1425.-)
Substantial amendments: 96 000 (approx. €645.-)
Bioavailability study: 70 000 (approx. €470.-)
In case of a need for external experts hired by the IMA: additional costs apply

In exceptional circumstances the fee for clinical trials can be waived if there is a valid rationale for doing so as in academic trials.

Waiver for academic (non-commercial) studies possible

Yes

Payment requirements (timelines)

After receipt of invoice

Official guidance on required fees available

Yes

Official guidance on required fees

Related information is available on the IMA website in section Home > IMA > Fees

Applicable national legal framework/ Reference

Annex 1, TARIFF No. 635/2011 for marketing authorisations, annual fees and other licence fees for medicinal products and related products, collected by the Icelandic Medicines Agency

Additional Information

Waiver for academic trials: There are no waive forms, but is has to be requested in the application and justification provided for the waiver.

Timelines Authorisation

General timespan (max nr days)

60

Mode of approval (General)

Tacit (Silent)

ATMP/GMO trials (max nr days)

90

Mode of approval (ATMP/GMO trials)

Explicit (authorisation in writing)

External expert advice required (max nr days)

180

Xenogeneic cell therapy (max nr days)

No time limit

Mode of approval (Xenogeneic cell therapy)

–

Timespan counted from

Date of submission of valid application

National legal framework in place

Yes

	Applicable national legal framework/ Reference Art 12-14 Regulation no 433/2004 **Additional Information** Explicit approval is also applicable to MP developed by biotechnological methods wor where the active ingredient is a bilogical product. NB! During summer holidays no clinical trial applications will be confirmed. The holidays are published on the IMA website in section Home > Licences > Clinical Trials > Application.
Amendments/ Substantial Amendments (SA)	**Notification mandatory for** – **Authorisation mandatory for** All substantial amendments to the study protocol (+ related information) **Responsible for submission of SA** Sponsor Principal Investigator (if no sponsor related to study) **Standard notification form available** Yes **Standard notification form** European Substantial Amendment Notification Form **Timeline for approval of SA (max nr days)** 35 By silent (implicit) approval **National legal framework in place** Yes **Applicable national legal framework/ Reference** Art 15 & 31 Regulation no 433/2004
Safety Reporting	**Responsible for AE reporting to CA** Sponsor Principal Investigator (if no sponsor related to study) **Sponsor must declare reportable events to** National CA EMA Eudravigilance CT Module (EVCTM) Relevant EC(s) **Reportable AEs** SAE (Serious Adverse Event) SUSAR (Suspected Unexpected Serious Adverse Reaction) **SUSAR being life-thereatening or leading to death must be reported** Within a max of 7d upon first knowledge (+ 8d for additional information) **All other SUSARs** Within a max of 15d upon first knowledge **SAE /SADE must be reported** –

National standard reporting form available

No, European standard SUSAR reporting form CIOMS-I recommended

Standard Reporting Form

CIOMS form (if sponsor does not have access to the EudraVigilance)

Reporting format - Options

Online portal
Electronically

Preferred format

–

Online Safety Reporting Portal

Sponsors shall report SUSARs to EMA´s database, EudraVigilance (IMA has access to information in the database and does not require copies of these reports). If the sponsor does not have access to the EudraVigilance, SUSARs should be reported to IMA electronically on CIOMS forms.

Provision of Annual safety report mandatory

Yes

Annual safety report shall be provided by sponsor to

National CA
Relevant EC(s)

Guidance on AE reporting procedure available

Yes

Guidance on AE reporting procedure

Related information is provided on the IMA website in section Home > Licences > Clinical Trials > SUSAR reporting (OR Home > Licences > Clinical Trials > Notification and Reports)

National legal framework in place

Yes

Applicable national legal framework/ Reference

Art 29 Regulation no 443/2004
Art 33 Regulation no 433/2004

Investigator shall report SAE to

Sponsor (if AE is fatal, IMA and the EC concerned must also be notified)

Reporting timeline

Immediately (without delay)

End of Trial

End of trial declaration mandatory for

All clinical investigations requiring authorisation by CA

Responsible for End of trial declaration

Sponsor
Principal Investigator (if no sponsor related to study)

Regular Termination - Declaration timespan (max nr days)

90

Timespan counted from

–

Early/premature Termination - Declaration timespan (max nr days)

15

Reasons for early termination shall be clearly stated

Yes

Standard Declaration form available

Yes

Standard Declaration form

European Declaration of the End of Trial Form

Guidance on End of trial declaration available

Yes

Guidance on End of trial declaration

Standard declaration form to be used (Declaration of the End of Trial Form) + related information is available on the IMA website in section Home > Licences > Clinical Trials > Notification and Reports

National legal framework in place

Yes

Applicable national legal framework/ Reference

Art 17 Regulation no 433/2004

Ethics committee

Contact Details

Contact Name 1

The National Bioethics Committee - NBC (Vísindasiðanefnd)

Phone

+354 5517100

Address

Borgartún 21

ZIP/City

101 Reykjavík

Country

Iceland (IS)

E-Mail

vsn@vsn.is

Web address

http://www.vsn.is/en

Ethical Review – General

Submission for Ethical review mandatory for

All scientific health research projects
Clinical IMP trials
Clinical ATMP trials

Submission to CA and EC to be performed in the following order

In parallel
Sequentially (in any order)

	Regulatory and ethics bodies involved in approval process –
Single-Centre Studies - Ethical Review	**Ethical approval (favourable opinion) to be obtained from** Central EC Institutional EC **Additional Information** All scientific health research projects as well as applications concerning clinical trials shall be approved by the NBC or the local Institutional Review Boards (for ethical review pursuant to Art 12 Scientific Research Act 44/2014). All clinical pharmaceutical studies involving human beings shall be submitted to the NBC.
Multi-Centre Studies - Ethical Review	**Ethical approval (favourable opinion) required from** Central EC (authorised to issue a single opinion) **Submission of application required to** Central EC (authorised to issue a single opinion) **Additional Information** Pursuant to Art 3 Regulation no 433/2004, a trial supervisor must be in place for national or international multi-centre trials where more than one Icelandic centre.is involved.
Submission of Application	**Responsible for study submission** Sponsor Principal Investigator (if no sponsor related to study) **Entitled to study submission** – **Prerequisites for submission / approval** – **Guidance on study submission available** Yes **Guidance on study submission** Related information and required documentation for application is set out in Art 6 Regulation no 433/2004. **National legal framework in place** Yes **Applicable national legal framework/ Reference** Art 6 Regulation no 433/2004
Submission Format	**Format option(s)** Email (vsn@vsn.is) **Preferred format** Email (vsn@vsn.is) **Standard application form available** Yes

	Standard application form The standard application form (including guidelines) and the checklist (that must be enclosed!) is available on the NBC website in section in Clinical Trials » Application form and a checklist for clinical trials. **Guidance on submission format available** Yes **Guidance on submission format** The standard application form includes guidelines and is available for download on the NBC website in section in Clinical Trials » Application form and a checklist for clinical trials.
Language of Submission	**Language(s) of application** Icelandic English **Preferred language of application** – **English accepted** – **Documents mandatory to be in official national language** Information material, Documents and Forms intended for study participants and patient information Item A3 of the application form (summary of study objective) + title of study **Additional Information** Related information is provided on the NBC website in section Home » Clinical trials » Application form and a checklist for clinical trials.
Submission Fees	**Fees for Ethical review mandatory** No **Fees for Ethical review** The service of the committees is free of charge.
Timelines Ethical Review	**General timespan for single-centre studies (max nr days)** 60 **General timespan for multi-centre studies (max nr days)** 60 **ATMP/GMO trials (max nr days)** 90 **External expert advice required: Timespan (max nr days)** 180 **Xenogeneic cell therapy: Timespan (max nr days)** No time limit **Clock-stop possible if complementary information requested** Yes **Timespan counted from** Date of submission of valid application

	National legal framework in place Yes **Applicable national legal framework/ Reference** Art 6 Regulation no 433/2004 **Additional Information** The NBC shall submit its reasoned opinion on ethical issues to the applicant and the Icelandic Medical Agency (IMA).
Amendments/ Substantial Amendments (SA)	**Ethical review mandatory for** Any substantial amendments to the study protocol **Responsible for notification of SA** Sponsor Investigator **Timeline Ethical review of SA (max nr days)** 35 **Guidance on submission of SA** Related information is available on the NBC website in section Clinical Trials » Amendments to Clinical Trial Protocols **Applicable national legal framework/ Reference** Art 15 Regulation no 433/2004 **Additional Information** NB! Substantial alteration in the handling of personal information may be subject for consideration by the Data Protection Authority.
Safety Reporting	**Reportable AEs** SAE (Serious Adverse Event) SUSAR (Suspected Unexpected Serious Adverse Reaction) **Investigator shall report SAE to** Sponsor (if AE is fatal, IMA and the EC concerned must also be notified) **Reporting timeline** Immediately (without delay) **Responsible for AE reporting to relevant EC(s)** Sponsor Principal Investigator (if no sponsor related to study) **SUSAR being life-thereatening or leading to death must be reported** Within a max of 7d upon first knowledge **All other SUSAR must be reported** Within a max of 15d upon first knowledge **SAE/SADE must be reported** – **National Standard Reporting form available** – **Reporting format - Options** –

Preferred reporting format

–

Provision of Annual safety report mandatory

Yes

National legal framework in place

Yes

Applicable national legal framework/ Reference

Art 29,30,33 Regulation no 443/2004

Additional Information

Annual safety report is mandatory to be submitted to IMA and the NBC (Art 33 Regulation no 433/2004)

End of Trial

End of trial Declaration mandatory

Yes

Responsible for End of trial Declaration

Sponsor
Investigator

Regular Termination - Declaration timespan (max nr days)

90

Timespan counted from

–

Early/premature Termination - Declaration timespan (max nr days)

15

Reasons for early termination shall be clearly stated

Yes

National legal framework in place

Yes

Applicable national legal framework/ Reference

Art 17 Regulation no 433/2004

Study specific Requirements

Sponsor

Sponsor - Definition available in national law

Yes

Sponsor - Definition (pursuant to national law)

An individual, company, institution, organisation or enterprise whose role is to initiate, manage and/or finance a clinical trial of a medicinal product (Art 2(i) Regulation no 433/2004).

Sponsorship mandatory - Additional information

If no sponsor is connected to the study, the principal investigator shall perform this role.

Co-Sponsor - Definition available in national law

No

	Additional Information Related details to study responsibilities are specified in Art 4 Regulation no 443/2004.
Investigator	**Entitled to be principal investigator** – **Additional Information** • Investigator: a physician or dentist authorised to carry out a clinical trial. If only one investigator is involved in a clinical trial of a medicinal product he/she is also regarded as the principal investigator. The investigator must fulfil suitable qualification as to education and professional expertise to be allowed to carry out a clinical trial. • Principal investigator: The investigator responsible for the implementation of a clinical trial of a medicinal product at each research centre. In certain instances the principal investigation may also be a sponsor, cf. item i. • Supervisor of the trial: The principal investigator who co-ordinates implementation of clinical trials on medicinal products in the Icelandic centres involved in a multi-centre trial. (Art 2 & Art 25 Regulation no 433/2004) Details to study responsibilities of investigators, principal investigators and sponsors are specified in Art 4 Regulation no 443/2004.
Study Participants - Informed Consent (IC)	**Standard IC form (ICF) available** Not specified **IC is regulated by law** Yes **Informed Consent - Definition/ Requirements** 'Consent shall be in writing and freely granted after the participant has been provided with adequate information on the study, risks it may entail, potential benefits, and the nature of the participation. The participant shall be informed that he/she may decline to take part in a scientific study, or withdraw from participation at any time after it commences, without stating any reason' **Applicable national legal framework/ Reference** Art 18 Scientific Research Act 2014 Related details including provisions applicable to vulnerable groups are set out in Section V, Art 18-24 Scientific Research Act 2014 and Chapter IV, Art 18-21 Regulation no 433/2004.
Study Participants - Vulnerable Population	**Minors / Children - Studies allowed** Yes Special provisions apply **Legal framework/Reference (Minors/Children)** Art 23 Scientific Research Act 2014 Art 19&20 Regulation no 433/2004 Detailed information is also provided on the NBC website in sections Home » Criteria » Vulnerable groups including Children **Incapacitated persons - Studies allowed** Yes Special provisions apply **Legal framework / Reference (Incapacitated persons)** Art 23 Scientific Research Act 2014 Art 19&20 Regulation no 433/2004

Emergency situations - Studies allowed

Yes
Special provisions apply

Emergency situation without prior consent of patient or proxy - Studies allowed

–

Conditions allowing trial participation in emergency setting without prior consent

In case that prior consent of the patient or of the next of kin can not be obtained, the study can be commenced if specific criteria are met:
a) patient's risk and burden are minor
b) patient is not opposed to participation
c) similar results cannot be achieved by research on individuals able to grant consent
d) the study is justified with regard to the potential for its findings being beneficial for the individual in question or individuals with the same disease, or promoting important preventive measure, diagnoses or cures
e) prior approval by the National Bioethics Committee or Institutional Review Board

The individual in question, or his/her next of kin, shall be provided with information on the study as soon as possible, and the appropriate consent shall be elicited for continuation of the study.

Legal framework / Reference (Emergency Situation)

Art 24 Scientific Research Act 2014

Pregnant or breastfeeding women - Studies allowed

Yes
Special provisions apply

Legal framework / Reference (Pregnant or breastfeeding women)

Specific requirements for vulnerable groups (as described on the NBC website in sections Home » Criteria » Vulnerable groups including Children) also apply to pregnant women (Art 15 Scientific Research Act 2014)

National legal framework for protection of vulnerable populations in place

Yes

Applicable legal framework / Reference (Vulnerable Population)

Provisions applicable to vulnerable groups are set out in Section V, Art 18-24 Scientific Research Act 2014 and Chapter IV, Art 18-21 Regulation no 433/2004.

Study Participants - Compensation & Reimbursement

Reimbursement for study participants

Not specified

Compensation is limited to/provided for

Not specified

Additional Information

No specific provisions provided in national law.

Data Protection

Notification to DP Authority/ Ombudsmann is mandatory

Yes

Approval/ authorisation required

Yes

Specific notification timelines before operations start

–

Language of notification

–

Notification format

–

Data Protection Authority/ Agency - Contact Details

Icelandic Data Protection Authority (Persónuvernd)

Phone

510 9600

Fax

510 9606

E-Mail

postur@personuvernd.is

Web address

http://www.personuvernd.is/information-in-english/

Address

Rauðarárstíg 10

ZIP/City

105 Reykjavík

Country

Iceland (IS)

Additional Information

Pursuant to Art 13 Scientific Research Act 2014, the National Bioethics Committee (NBC) shall as soon as possible submit a summary of each application to the Data Protection Authority for approval.

Data Protection Authority: shall issue an opinion and notify the NBE within 10 working days after receipt of the summary from the National Bioethics Committee.

Processing of personal data is subject to the provisions of the Data Protection Act 2000.

Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)

–

Insurance

Liability insurance or alternative arrangements for damages mandatory for

Investigator(s)
Sponsor
Study participants

Responsible for covering insurance

–

Applicable national legal framework/ Reference

Art 5&6 Regulation no 433/2004

Additional Information

Subjects participating in a clinical trial of a medicinal product must be sufficiently insured against conceivable damage to their health resulting from the trial.
The principal investigator or, as the case may be, the investigator shall be responsible for ensuring satisfactory insurance coverage.
Insurance or compensation to cover the liability of the investigator and sponsor for compensation.

Quality Assurance/ Quality Control (QA/QC)

Monitoring

Compulsory

Audit by sponsor

Optional

Standard Operating Procedures (SOPs)

Compulsory

Archiving & Data Management

Study documents must be kept at least (in years)

–

National legal framework in place

Yes

Applicable national legal framework/ Reference

Art 33 Regulation no 433/2004

Additional Information

Clinical records of participants in the studies shall be kept in accordance with applicable law on clinical records.

National legislation

General Information: Applicable Legislation & Conventions

Official website providing relevant national legislation available

Yes

Official website providing relevant national legislation

A list on legilsation applicable to scientific research is provided in English on the websites of:
• IMA in section Home » IMA » Laws and Legislation AND
• NBC in section Home » The Bioethics Committee System » Legal Framework

Official governmental legal database available

Yes

Official governmental legal database

The Ministry of Welfare and Ministry of Interior provide available English translation of legislation.

Clinical Trials on IMPs in Humans

Applicable national regulations

General Act(s) on Medical/Clinical Research in Humans
National Act on Medicinal Products
Transposition of (CT) Directive 2001/20/EC
Transposition of Directive 2001/83/EC

	Transposition of (CT) Directive 2001/20/EC (or comparable national legal framework) Regulation on clinical trials of medicinal products in humans, No. 443/2004 (as amended by Regulations No. 907/2004 and No. 1099/2010) („Regulation no 443/2004“): This regulation implements Directive 2001/20/EC as well as Directive 2001/83/EC on medicinal products for humans) It covers bioavailability and bioequivalence studies, applies to radioactive medicines, natural medicines, homeopathic medicines, medicines for gene-therapy or for remedy with body cells and medicines, which contain genetically modified organisms NB! Not applicable to non-interventional investigation! **Applicable to ATMP/ GMO trials** Yes **Transposition of (GCP) Directive 2005/28/EC** – **General legislation on Medical/ Clinical Research in Humans** Act on Scientific Research in the Health Sector No. 44/2014 („Scientific Research Act 2014“). It applies to scientific studies carried out, in whole or in part, in Iceland. **Other applicable regulations/ implementing provisions (Acts, laws, decrees, ordinances, circulars, etc)** (1) Medicinal Products Act, No. 93/1994, as amended. (2) Insurance: Act on Patient Insurance, No. 111/2000, as amended: Patients who suffer physical or mental damage in connection with examination or medical treatment in a hospital, health-care centre or other health institution are covered by this act.
Radiation & Radiotherapy	**Use of radiation or radioactive compounds - Specific requirements** Yes **Applicable legal framework** Clinical trials on radioactive medicines are covered by Regulation no 443/2004.
Biobanking	**Specific requirements** Yes **Applicable legal framework** Biobanks Act, No. 110/2000 It regulates the collection, keeping, handling and utilisation of human biological samples
Data Protection	**Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)** National Data Protection Act **National DP act** Act on the Protection of Privacy as regards the Processing of Personal Data No. 77/2000 (The Data Protection Act 2000) This act regulates the handling and processing of personal data in the context of scientific research clinical trials. It shall apply insofar as specific provisions of the Reg. 433/2004 do not take precedence.
CA operations/ Fees	**Separate legal framework available** Yes

Applicable legal framework

TARIFF No. 635/2011 for marketing authorisations, annual fees and other licence fees for medicinal products and related products, collected by the Icelandic Medicines Agency

Definition

IMP/IMP Study

IMP - Definition available in national law

Yes

IMP - Definition

'A pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical trial, including products already with a marketing authorisation but used or assembled (specially formulated or packaged) in a way different from the authorised form, or when used for an unauthorised indication, or when used to gain further information about the authorized form' (Art 2 Regulation no 433/2004)

IMP Study - Definition available in national law

Yes

IMP Study - Definition

'A clinical pharmaceutical study: A systematic testing of a medicine with the purpose of finding or confirming its effects and/or finding the side effects of the medicine and/or absorption, circulation, metabolism and the excretion of the drug with the purpose of checking its security and functionality.' (Art 2 Regulation no 433/2004)

Additional Information

Non-interventional study (definition pursuant to to Art 2 Regulation no 433/2004):
'A study where the medicinal product or products are prescribed in a normal manner in accordance with the terms of its marketing authorisation. Treatment of the patient is not pre-determined by a clinical trial protocol, but rather follows current practice. The instructions concerning the medicinal product are clearly separated from the decision that the patient shall take part in the trial. No supplementary analyses or supervision shall be carried out in treating the patient and epidemiological methods used in analysing the data collected.'